No, not crunches — trainer says these 5 bodyweight moves are the secret to building stronger abs
You don't need a gym full of weights to build the kind of core strength you're aiming for. While many people turn to weighted ab exercises, online trainer James Stirling says you can achieve it with just your bodyweight and shares his 30-minute routine to help you get there.
There aren't any of the same old classics like sit-ups and crunches, but instead a smart mix of isometric holds, controlled movements, and full-body stability work that hits your core from every angle.
This is a challenging core routine, but it's suitable for a range of fitness levels. Feel free to reduce the number of rounds or adjust rest times if it feels too intense. And if you're currently managing an injury or health concern, check in with a medical or fitness professional before giving it a go.
Watch The London Fitness Guy's No-Equipment Core Workout
I recommend watching the video from Stirling's Instagram page, where he regularly shares home-friendly strength-building routines. It shows him demonstrating all five moves, which I find really helpful when following a workout at home without a trainer there in person to correct my form.
Although I said it's a no-equipment routine, you may have noticed Stirling does the workout on a mat in his home. This helps cushion your back, bum, and joints while working through the exercises. If you're on the lookout for a suitable mat, I can point you in the direction of our hand-picked guide to the best yoga mats.
The Manduka Prolite is one of our top picks for a reason. It offers reliable grip and cushioning for everything from ab workouts to cooldown stretches. As my colleague Sam said in her review of the mat, it 'gives the right amount of grip and flexibility to flow between poses(/exercises)."View Deal
How do bodyweight moves build strength?
Bodyweight exercises like hollow holds, planks, and shoulder taps might look simple, but they can be incredibly effective for building strength, especially in your core. These moves use your own body as resistance, forcing your muscles to engage, stabilise, and control each movement.
While lifting weights involves external resistance, bodyweight training is still a form of resistance exercise. Instead of using dumbbells or gym machines, you work against gravity and your mass.
Exercises like Copenhagen planks or leg raises engage multiple muscle groups at once, which requires extra balance and control on less stable surfaces. That extra challenge encourages your core muscles to work harder and grow stronger in a way that supports everyday movement.
To see real progress, consistency and progression are key. You can increase the number of rounds, shorten your rest periods, or hold each move for longer to keep challenging your muscles. If you're just starting out, completing one or two circuits is a great foundation, and you can gradually build from there.
One of the biggest strengths of bodyweight routines is how easy they are to fit into your life. You do not need a gym or expensive gear, just a little space and the willingness to move. Whether you're fitting in a quick session between tasks or winding down in the evening with a short circuit, it is consistent effort that builds strength over time.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
Fibermaxxing is trending right now — here's what to know before you try it
Forget the sauna — soaking in a hot tub could be better for your health, says new study
I hiked through rain, wind and fog in the Rab Firewall Mountain Waterproof Jacket — here's my verdict
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
Yahoo
5 hours ago
- Yahoo
🚨 Ter Stegen undergoes successful surgery, return date still unknown
The operation of Marc André Ter Stegen has been confirmed. The FC Barcelona goalkeeper underwent surgery this Tuesday to address his lumbar issues. "The first team player Marc Ter Stegen has successfully undergone surgery again for his lumbar problems by Dr. Amélie Léglise, under the supervision of the Club's Medical Services, at the Sports Clinic Bordeaux Merignac. He is out and his recovery will determine his availability", reads the Barça statement. The club has not provided information regarding his recovery time. This has sparked a debate focusing on the situation of the Barça goalkeeping position. The difficulties in registering Joan García have prompted discussions on how many months Ter Stegen will be sidelined. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 Alex Grimm - 2025 Getty Images
Yahoo
5 hours ago
- Yahoo
Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars
Sarepta (SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug Administration (FDA) reversed its request for a voluntary pause late Monday. The news sent Sarepta's stock up sharply. The company extended gains Tuesday, with its stock up more than 40% in pre-market action. Sarepta had been trading down nearly 90% year-to-date after four patient deaths, and FDA probe and a European Medicines Agency panel recommending rejection of Elevidys pressured the company last week. "We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of Elevidys for ambulatory patients," said Sarepta CEO Doug Ingram, in a statement Monday. The FDA will continue to investigate the patient deaths, the latest of which was a 51-year-old patient in a clinical trial for a different muscular dystrophy drug. There was also an 8-year-old boy in Brazil, who died on June 7 from a different drug. There have been two Elevidys patient deaths reported this year. Analysts are cautiously optimistic about the shipments resuming, but are waiting to see the impact to the bottom line. The company has needed to continue strong sales of Elevidys in order to clear its $1.5 billion convertible debt due in 2027. "It seems like the FDA is listening to the community and this is great news for patients, but we remain on the sidelines until we gain better visibility into how demand trends, which is important from a balance sheet perspective," wrote Leerink Partners analyst Joseph Schwartz in a note to clients Monday. Jefferies analyst Andrew Tsai, one of the few which had maintained a Buy rating on the stock, said his firm did not doubt the company's ability to get the product back on the market, and is now watching how sales follow. "We were already unsure whether FDA could pull our premise was that Elevidys stays on the market ... though we also acknowledge Elevidys' sales outlook was looking murkier when SRPT went against the FDA's wishes (i.e. hospitals were starting to pause dosing)," Tsai wrote. "If SRPT's internal stress tests of the... franchise 'flooring' at $1.4B annually into the Street might have greater confidence in SRPT's ability to pay off the $1.1B+ of converts in 2027," he added. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data